| Literature DB >> 33745879 |
Sima Singh1, Arshid Numan2, Balaji Maddiboyina3, Saahil Arora4, Yassine Riadi5, Shadab Md6, Nabil A Alhakamy6, Prashant Kesharwani7.
Abstract
Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33745879 DOI： 10.1016/j.drudis.2021.03.011
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851